VCELHIGH SIGNALFINANCIAL10-K

VCEL delivered exceptional operational leverage with operating income surging 144% while revenue grew 16.5%, indicating significantly improved profitability and operational efficiency.

The company demonstrated strong execution with operating margins expanding dramatically as revenue growth outpaced expense growth. The substantial reduction in capital expenditures (-57.5%) alongside improved cash generation and higher receivables suggests VCEL has moved past a heavy investment phase into a more profitable operational period.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

VCEL showed exceptional financial performance with operating income more than doubling (+144%) while revenue grew a solid 16.5% to $276.3M, demonstrating powerful operational leverage. The company improved its balance sheet strength with cash rising 34% to $100M and stockholders' equity increasing 21%, while dramatically reducing capital expenditures by 57% from $64M to $27M. This financial profile suggests VCEL has successfully transitioned from a capital-intensive growth phase to a more profitable, cash-generative business model.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+144.4%
$4.5M$11.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+63.9%
$366K$600K

Interest expense surged 63.9% — significant debt increase or rising rates materially impacting earnings.

Net Income
P&L
+59.4%
$10.4M$16.5M

Net income grew 59.4% — bottom-line growth signals improving overall business health.

Capital Expenditure
Cash Flow
-57.5%
$64.0M$27.2M

Capex reduced 57.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+37.9%
$61.4M$84.6M

Receivables surged 37.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
+34.3%
$74.5M$100.1M

Cash position surged 34.3% — strong cash generation or capital raise providing significant financial cushion.

Stockholders Equity
Balance Sheet
+21.5%
$292.0M$354.6M

Equity base grew 21.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+19.5%
$172.1M$205.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+16.9%
$142.8M$167.0M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Revenue
P&L
+16.5%
$237.2M$276.3M

Revenue growing 16.5% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 5 7 Item 6.
All other trade names, trademarks and service marks of other companies appearing in this Form 10-K are the property of their respective holders, including NexoBrid, which is a registered trademark of MediWound Ltd.
Business General Information Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets.
We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies.
during the third quarter of 2024, and the Company began selling MACI Arthro instruments at that time.
+7 more — sign up free →
REMOVED
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 58 Item 6.
We own various trademark registrations and applications, and unregistered trademarks, including Vericel Corporation, Epicel, MACI, MACI Arthro and our corporate logo.
Business General Information Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leading provider of advanced therapies for the sports medicine and severe burn care markets.
Whether we are treating damaged cartilage or severe burns, we provide advanced therapies to repair serious injuries and restore lives.
Our highly differentiated portfolio of cell therapy and specialty biologic products combines innovations in biology with medical technologies.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →